Literature DB >> 11827268

Assessing risk factors for systemic fungal infections.

J Maertens1, M Vrebos, M Boogaerts.   

Abstract

The incidence of invasive fungal infection has increased in recent years. Most infections are caused by Candida albicans and Aspergillus spp. but the emergence of other fungal infections is changing the spectrum of disease. Immunosuppression and breakdown of anatomical barriers such as the skin are the major risk factors for fungal infections. Health care workers encounter at-risk patients in various settings, including AIDS clinics and intensive care, transplantation and oncology units. Patients with prolonged and deep neutropenia (haematological malignancy patients) are most at risk and are therefore most likely to receive prophylactic therapy. Practical measures can be taken to avoid exposing the patient to fungi (air filtration, regular hand washing, avoiding plants and flowers) and antifungal agents can be administered to prevent systemic fungal infection. Most fungal infections have non-specific symptoms; this makes recognition of the signs and symptoms of the disease important but also makes diagnosis difficult and empirical treatment necessary. Some antifungal agents have limitations but new formulations will improve therapy and play a key role in future antifungal strategies.

Entities:  

Mesh:

Year:  2001        PMID: 11827268     DOI: 10.1046/j.1365-2354.2001.00241.x

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  33 in total

1.  Systematic internal transcribed spacer sequence analysis for identification of clinical mold isolates in diagnostic mycology: a 5-year study.

Authors:  Diana E Ciardo; Katja Lucke; Alex Imhof; Guido V Bloemberg; Erik C Böttger
Journal:  J Clin Microbiol       Date:  2010-06-23       Impact factor: 5.948

2.  Internal transcribed spacer sequencing versus biochemical profiling for identification of medically important yeasts.

Authors:  D E Ciardo; G Schär; E C Böttger; M Altwegg; P P Bosshard
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

3.  Expression of an additional cathelicidin antimicrobial peptide protects against bacterial skin infection.

Authors:  Phillip H A Lee; Takaaki Ohtake; Mohamed Zaiou; Masamoto Murakami; Jennifer A Rudisill; Kenneth H Lin; Richard L Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

4.  A Systematic Screen Reveals a Diverse Collection of Medications That Induce Antifungal Resistance in Candida Species.

Authors:  Arielle Butts; Parker Reitler; Andrew T Nishimoto; Christian DeJarnette; Leanna R Estredge; Tracy L Peters; Michael P Veve; P David Rogers; Glen E Palmer
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 5.  Th17 cells in immunity to Candida albicans.

Authors:  Nydiaris Hernández-Santos; Sarah L Gaffen
Journal:  Cell Host Microbe       Date:  2012-05-17       Impact factor: 21.023

6.  A novel polyamide SL-A92 as a potential fungal resistance blocker: synthesis and bioactivities in Candida albicans.

Authors:  Shao-long Zhu; Zhi-hui Jiang; Ping-hui Gao; Yue Qiu; Liang Wang; Yuan-ying Jiang; Da-zhi Zhang
Journal:  Acta Pharmacol Sin       Date:  2010-06-21       Impact factor: 6.150

7.  Efficient bioconversion of echinocandin B to its nucleus by overexpression of deacylase genes in different host strains.

Authors:  Lei Shao; Jian Li; Aijuan Liu; Qing Chang; Huimin Lin; Daijie Chen
Journal:  Appl Environ Microbiol       Date:  2012-12-07       Impact factor: 4.792

Review 8.  Posaconazole : a review of its use in the prophylaxis of invasive fungal infections.

Authors:  James E Frampton; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Immunoparalysis as a cause for invasive aspergillosis?

Authors:  Koen J Hartemink; Marinus A Paul; Jan Jaap Spijkstra; Armand R J Girbes; Kees H Polderman
Journal:  Intensive Care Med       Date:  2003-05-24       Impact factor: 17.440

Review 10.  Optimizing efficacy of Amphotericin B through nanomodification.

Authors:  Gillian Barratt; Stéphane Bretagne
Journal:  Int J Nanomedicine       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.